About Us

Synchroneuron is a privately held, clinical-stage biopharmaceutical company developing novel treatments for movement disorders and other neuropsychiatric conditions where there are pressing unmet patient needs for safe and effective therapies.

 

Our Technology

Synchroneuron has developed a novel sustained-release formulation of acamprosate calcium. Acamprosate has been reformulated to improve its GI tolerability, dosing schedule and pharmacokinetic profile.

 

Clinical Indications

Synchroneuron has leveraged its understanding of acamprosate’s unique mechanism of action to develop SNC-102 as a promising new treatment option for patients with neuropsychiatric disorders including tardive dyskinesia, Tourette syndrome and combat-related posttraumatic stress disorder.